Current Topics in Oncology: A Focus on TKIs in Solid Tumors

Download All
Get up to date with expert discussions on leveraging TKIs for patients with solid tumors in this podcast series accompanied by downloadable summary slidesets.
person default
Jean Yves Blay, MD, PhD
Robin L. Jones, BSc, MBBS, MRCP, MD(Res)
Josep M. Llovet, MD
Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA

Podcasts

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss key data on using TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.

person default Jean Yves Blay, MD, PhD Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Released: November 2, 2021

Download this summary slideset to accompany a podcast featuring expert discussion on key clinical trial data on leveraging TKIs as single agents or in combination with cytotoxics or immune checkpoint inhibitors for treatment of soft tissue sarcomas and osteosarcoma.

person default Jean Yves Blay, MD, PhD Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Released: November 3, 2021

In this podcast episode, experts Josep M. Llovet, MD, PhD, and Univ. Prof. Markus Peck-Radosavljevic, MD, MBA, discuss the evolving role of tyrosine kinase inhibitors in the first-line treatment of patients with advanced hepatocellular carcinoma.

Josep M. Llovet, MD Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA Released: December 14, 2021

Summary slides for a podcast where Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss the evolving role of tyrosine kinase inhibitors in the first-line treatment of patients with advanced hepatocellular carcinoma.

Josep M. Llovet, MD Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA Released: December 14, 2021

In this podcast episode, experts Josep M. Llovet, MD, PhD, and Univ. Prof. Markus Peck-Radosavljevic, MD, MBA, discuss the role of tyrosine kinase inhibitors in treating patients with advanced HCC in the second line and beyond.

Josep M. Llovet, MD Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA Released: February 22, 2022

Summary slides for a podcast where Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss the role of tyrosine kinase inhibitors in the second-line treatment of patients with advanced hepatocellular carcinoma.

Josep M. Llovet, MD Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA Released: February 22, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings